A 2015 review found that adding<unk>  to statin treatment of high blood cholesterol had no effect on overall mortality or cardiovascular mortality, although it significantly reduced the risk of myocardial infarction and stroke. A 2015 trial found that adding<unk>  to simvastatin had no effect on overall mortality but did lower the risk of heart attack or stroke in people with prior heart attack. Several treatment guidelines recommend adding<unk>  in select high risk persons in whom LDL goals cannot be achieved by maximally tolerated statin alone.<unk>  is indicated in the United States as an add-on to dietary measures to reduce levels of certain lipids in people with: *Primary hyperlipidemia, alone or with a statin *Mixed hyperlipidemia, in combination with fenofibrate *Homozygous familial hypercholesterolemia, in combination with specific statins *Homozygous sitosterolemia A 2018 review found that<unk>  used as sole treatment slightly lowered plasma levels of lipoprotein(a), but the effect was not large enough to be important.<unk>  improves the non-alcoholic fatty liver disease activity score but the available evidence indicates it does not improve outcomes of hepatic steatosis.
Ezetimibe
Clofibrate
Fenofibrate
Simvastatin
Lovastatin
Gemfibrozil
Fluvastatin
Atorvastatin